Jade Biosciences (JBIO) Change in Accured Expenses (2020 - 2026)
Jade Biosciences posted quarterly Change in Accured Expenses of $5.8 million for Q1 2026, up 396.3% year-on-year from $1.2 million in Q1 2025, and up 265.1% on a QoQ basis from -$3.5 million in Q4 2025.
Jade Biosciences (JBIO) has 7 years of Change in Accured Expenses data on file, last reported at $5.8 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 396.3% year-over-year to $5.8 million; the trailing twelve-month figure through Mar 2026 stood at $11.7 million (up 306.98% YoY), and the FY2025 full-year result was $3.9 million, up 2319.63% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $5.8 million, up from -$3.5 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $10.1 million in Q4 2023 and bottomed at -$3.5 million in Q4 2025.
- The 5-year median for Change in Accured Expenses is $497000.0 (2022), against an average of $1.5 million.
- Peak annual rise in Change in Accured Expenses reached 5257.14% in 2022, while the deepest fall reached 6648.15% in 2022.
- A 5-year view of Change in Accured Expenses shows it stood at -$1.8 million in 2022, then soared by 672.0% to $10.1 million in 2023, then plunged by 60.64% to $4.0 million in 2024, then tumbled by 187.84% to -$3.5 million in 2025, then soared by 265.1% to $5.8 million in 2026.
- The last three Change in Accured Expenses figures came in at $5.8 million (Q1 2026), -$3.5 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Jade Biosciences | 1.06 Bn | 1.06 Bn | - | 5.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.77 Mn |
| Mar 31, 2026 | 5.77 Mn |
| Dec 31, 2025 | -3.50 Mn |
| Dec 31, 2025 | -3.50 Mn |
| Sep 30, 2025 | 4.58 Mn |
| Sep 30, 2025 | 4.58 Mn |
| Jun 30, 2025 | 4.81 Mn |
| Jun 30, 2025 | 4.81 Mn |
| Mar 31, 2025 | -1.95 Mn |
| Mar 31, 2025 | -1.95 Mn |
| Dec 31, 2024 | 3.98 Mn |
| Dec 31, 2024 | 3.98 Mn |
| Sep 30, 2024 | 244,000.00 |
| Sep 30, 2024 | 244,000.00 |
| Jun 30, 2024 | 590,000.00 |
| Jun 30, 2024 | 590,000.00 |
| Mar 31, 2024 | 392,000.00 |
| Mar 31, 2024 | 392,000.00 |
| Dec 31, 2023 | 10.11 Mn |
| Dec 31, 2023 | 10.11 Mn |
| Sep 30, 2023 | 111,000.00 |
| Sep 30, 2023 | 111,000.00 |
| Jun 30, 2023 | -941,000.00 |
| Jun 30, 2023 | -941,000.00 |
| Mar 31, 2023 | 716,000.00 |
| Mar 31, 2023 | 716,000.00 |
| Dec 31, 2022 | -1.77 Mn |
| Dec 31, 2022 | -1.77 Mn |
| Sep 30, 2022 | 1.44 Mn |
| Sep 30, 2022 | 1.44 Mn |
| Jun 30, 2022 | -306,000.00 |
| Jun 30, 2022 | -306,000.00 |
| Mar 31, 2022 | 497,000.00 |
| Mar 31, 2022 | 497,000.00 |
| Dec 31, 2021 | 27,000.00 |
| Dec 31, 2021 | 27,000.00 |
| Sep 30, 2021 | -28,000.00 |
| Sep 30, 2021 | -28,000.00 |
| Jun 30, 2021 | 919,000.00 |
| Jun 30, 2021 | 919,000.00 |
| Mar 31, 2021 | -924,000.00 |
| Mar 31, 2021 | -924,000.00 |
| Dec 31, 2020 | 618,000.00 |
| Dec 31, 2020 | 618,000.00 |
| Sep 30, 2020 | 121,000.00 |
| Sep 30, 2020 | 121,000.00 |